United States — Centers for Disease Control and Prevention & Pfizer

United States — Centers for Disease Control and Prevention: The United States — Centers for Disease Control and Prevention (CDC) provides crucial data on Lyme disease incidence and issues advisories regarding tick season severity, highlighting the public health need for a vaccine. The CDC's data supports the importance of the vaccine being developed by Pfizer and Valneva SE.

Pfizer: Pfizer is a pharmaceutical company developing a new Lyme disease vaccine, which has shown 70-75% effectiveness in late-stage studies. The company plans to seek regulatory approval, which could significantly boost its market position in infectious disease prevention.

United States — Centers for Disease Control and Prevention: The United States — Centers for Disease Control and Prevention provides statistics on RSV hospitalizations, underscoring the public health challenge that the vaccine aims to address.

Pfizer: Pfizer manufactures the RSVpreF vaccine, which has shown significant effectiveness in preventing RSV-associated hospitalizations in infants. This positive real-world data validates their product and could lead to increased sales and market share in the vaccine segment.